1Wakabayashi K, Saito H, Kaneko F, et al.Gene expression associated with the decrease in malignant phenotype of human liver cancer ceils following stimulation with a histone deacetylase inhibitor. Int J Oncol, 2005,26 :233-239.
2Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res, 2005, 65: 3980-3985.
4Gabrilli BG,Johnstone RW,Saunders NA.dentifying molecular targets mediating the anticancer activity of histone doacetylase inhibitors:a work in progress Curr Cancer Drug Targets,2002,2:337-353.
5Marks PA,Richon VM,Breslgw R,et al.Histone deacetylase inhibitors as new cancer drugs,Curr Opln Oncol,2001,13:477-483.
6Knsugi H,Towatari M,Hatano S,et al.Histone deacetylase inhibitors are the potent omfivrt/enhancer of differentiation in acute myeloid leukemia:a new approach to anti-leukemia therapy.Leukemia,1999,13:1316-1324.
7Hirsch CL,Smith-Windsor El,Bonham K,Sro family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.Int J Cancer,2006,118:547-554.
8Zhong L, D ' Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1a. Cell,2010,140:280-293.
9Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet,2009 ,10 :32-42.
10Mostoslavsky R, Chua KF, Lombard DB,et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell, 2006,124 : 315-329.
